CARDIFF ONCOLOGY, INC. Total Shareholder Rtn Amt
CARDIFF ONCOLOGY, INC. (CRDF) reported Total Shareholder Rtn Amt of $201 for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-04-23.
Financial Statements › Notes
ecd:TotalShareholderRtnAmt · last filed 2026-04-23
| Period end | Total Shareholder Rtn Amt 12 month |
|---|---|
| 2025-12-31 | $201.00 DEF 14A · filed 2026-04-23 |
| 2024-12-31 | $310.00 DEF 14A · filed 2026-04-23 |
| 2023-12-31 | $106.00 DEF 14A · filed 2026-04-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |